Istituto di Medicina Interna e Geriatria, Policlinico A. Gemelli, Università Cattolica del S. Cuore, L.go A. Gemelli, 8 00168 Roma, Italy.
Expert Rev Clin Pharmacol. 2009 Jul;2(4):391-403. doi: 10.1586/ecp.09.12.
Over the last few years, advances in understanding the pathogenesis of inflammatory bowel disease, together with progress in biotechnology, have led to the availability of several biological drugs that have dramatically changed the therapeutic approach to these disorders. Indeed, several molecules targeting crucial inflammatory cytokines, blocking T-cell activation/proliferation or the recruitment of inflammatory cells into the inflamed bowel, have been discovered and commercialized. However, the increasing use of biological agents has raised some concerns regarding their short- and long-term safety. This review offers a critical evaluation of the efficacy and safety of biological agents in the management of both Crohn's disease and ulcerative colitis. In addition, promising therapeutic options are discussed.
在过去的几年中，对炎症性肠病发病机制的认识的进步，以及生物技术的进步，导致了几种生物药物的出现，这些药物极大地改变了对这些疾病的治疗方法。事实上，已经发现并商业化了几种针对关键炎症细胞因子的分子，这些分子可以阻断 T 细胞的激活/增殖或炎症细胞招募到炎症肠道中。然而，生物制剂的使用越来越多，引起了人们对其短期和长期安全性的一些关注。这篇综述对生物制剂在克罗恩病和溃疡性结肠炎治疗中的疗效和安全性进行了批判性评估。此外，还讨论了有前途的治疗选择。
